Regulation of p53 stability and activity in response to genotoxic stress

Mutation Research-Reviews in Mutation Research

Volumn 462, Issue 2-3, 2000, Pages 179-188

  Colman, Michael S ^a   Afshari, Cynthia A ^a   Barrett, J Carl ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

Adaptation; Apoptosis; Genotoxic stress; MDM2; p53

Indexed keywords

MUTAGENIC AGENT; PROTEIN P53;

ACETYLATION; ADAPTATION; APOPTOSIS; CANCER INHIBITION; DNA DAMAGE; GENOTOXICITY; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; REVIEW; SIGNAL TRANSDUCTION;

DNA DAMAGE; GENE EXPRESSION REGULATION; HUMANS; MUTAGENS; NUCLEAR PROTEINS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034032170     PISSN: 13835742     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1383-5742(00)00035-1     Document Type: Article

References (79)

1. Liu Z.G., Baskaran R., Lea-Chou E.T., Wood L.D., Chen Y., Karin M., Wang J.Y. Three distinct signalling responses by murine fibroblasts to genotoxic stress [see comments]. Nature. 384:1996;273-276.
2. Sherr C.J. Cancer cell cycles. Science. 274:1996;1672-1677.
3. Beroud C., Soussi T. p53 gene mutation: software and database. Nucleic Acids Res. 26:1998;200-204.
4. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell. 88:1997;323-331.
5. Ko L.J., Prives C. p53: puzzle and paradigm. Genes Dev. 10:1996;1054-1072.
6. Polyak K., Xia Y., Zweier J.L., Kinzler K.W., Vogelstein B. A model for p53-induced apoptosis [see comments]. Nature. 389:1997;300-305.
7. Ngan H.Y., Cheung A.N., Liu S.S., Yip P.S., Tsao S.W. Abnormal expression or mutation of TP53 and HPV in vulvar cancer. Eur. J. Cancer. 35:1999;481-484.
8. Sonoda Y., Saigo P.E., Boyd J. p53 and genetic susceptibility to cervical cancer. J. Natl. Cancer Inst. 91:1999;557.
9. Hildesheim A., Schiffman M., Brinton L.A., Fraumeni J.F. Jr., Herrero R., Bratti M.C., Schwartz P., Mortel R., Barnes W., Greenberg M., McGowan L., Scott D.R., Martin M., Herrera J.E., Carrington M. p53 polymorphism and risk of cervical cancer. Nature. 396:1998;531-532.
10. Siliciano J.D., Canman C.E., Taya Y., Sakaguchi K., Appella E., Kastan M.B. DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev. 11:1997;3471-3481.
11. Canman C.E., Lim D.S. The role of ATM in DNA damage responses and cancer. Oncogene. 17:1998;3301-3308.
12. Schaffner C., Stilgenbauer S., Rappold G.A., Dohner H., Lichter P. Somatic ATM mutations indicate a pathogenic role of ATM of B-cell chronic lymphocytic leukemia. Blood. 94:1999;748-753.
13. Stoppa-Lyonnet D., Soulier J., Lauge A., Dastot H., Garand R., Sigaux F., Stern M.H. Inactivation of the ATM gene in T-cell prolymphocytic leukemias. Blood. 91:1998;3920-3926.
14. Piette J., Neel H., Marechal V. MDM2: keeping p53 under control. Oncogene. 15:1997;1001-1010.
15. Prives C. Signaling to p53: breaking the MDM2-p53 circuit. Cell. 95:1998;5-8.
16. Shieh S.Y., Ikeda M., Taya Y., Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell. 91:1997;325-334.
17. Unger T., Juven-Gershon T., Moallem E., Berger M., Vogt Sionov R., Lozano G., Oren M., Haupt Y. Critical role for Ser20 of human p53 in the negative regulation of p53 by MDM2. EMBO J. 18:1999;1805-1814.
18. Wu L., Levine A.J. Differential regulation of the p21/WAF-1 and MDM2 genes after high-dose UV irradiation: p53-dependent and p53-independent regulation of the MDM2 gene. Mol. Med. 3:1997;441-451.
19. Reinke V., Lozano G. The p53 targets MDM2 and Fas are not required as mediators of apoptosis in vivo. Oncogene. 15:1997;1527-1534.
20. Lozano G., Montes de Oca Luna R. MDM2 function. Biochim. Biophys. Acta. 1377:1998;M55-59.
21. Roth J., Dobbelstein M., Freedman D.A., Shenk T., Levine A.J. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J. 17:1998;554-564.
22. Haupt Y., Maya R., Kazaz A., Oren M. MDM2 promotes the rapid degradation of p53. Nature. 387:1997;296-299.
23. Kubbutat M.H., Ludwig R.L., Levine A.J., Vousden K.H. Analysis of the degradation function of MDM2. Cell Growth Differ. 10:1999;87-92.
24. Freedman D.A., Levine A.J. Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol. Cell. Biol. 18:1998;7288-7293.
25. Tao W., Levine A.J. Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53. Proc. Natl. Acad. Sci. U.S.A. 96:1999;3077-3080.
26. Honda R., Tanaka H., Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420:1997;25-27.
27. Kussie P.H., Gorina S., Marechal V., Elenbaas B., Moreau J., Levine A.J., Pavletich N.P. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain [comment]. Science. 274:1996;948-953.
28. Ashcroft M., Kubbutat M.H., Vousden K.H. Regulation of p53 function and stability by phosphorylation. Mol. Cell. Biol. 19:1999;1751-1758.
29. Blattner C., Tobiasch E., Litfen M., Rahmsdorf H.J., Herrlich P. DNA damage induced p53 stabilization: no indication for an involvement of p53 phosphorylation. Oncogene. 18:1999;1723-1732.
30. Mayo L.D., Turchi J.J., Berberich S.J. MDM-2 phosphorylation by DNA-dependent protein kinase prevents interaction with p53. Cancer Res. 57:1997;5013-5016.
31. Pomerantz J., Schreiber-Agus N., Liegeois N.J., Silverman A., Alland L., Chin L., Potes J., Chen K., Orlow I., Lee H.W., Cordon-Cardo C., DePinho R.A. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell. 92:1998;713-723.
32. Zhang Y., Xiong Y., Yarbrough W.G. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell. 92:1998;725-734.
33. Chang Y.C., Lee Y.S., Tejima T., Tanaka K., Omura S., Heintz N.H., Mitsui Y., Magae J. mdm2 and bax, downstream mediators of the p53 response, are degraded by the ubiquitin-proteasome pathway. Cell Growth Differ. 9:1998;79-84.
34. Honda R., Yasuda H. Association of p19(ARF) with MDM2 inhibits ubiquitin ligase activity of MDM2 for tumor suppressor p53. EMBO J. 18:1999;22-27.
35. Stott F.J., Bates S., James M.C., McConnell B.B., Starborg M., Brookes S., Palmero I., Ryan K., Hara E., Vousden K.H., Peters G. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 17:1998;5001-5014.
36. Sionov R.V., Moallem E., Berger M., Kazaz A., Gerlitz O., Ben-Neriah Y., Oren M., Haupt Y. c-Abl neutralizes the inhibitory effect of MDM2 on p53. J. Biol. Chem. 274:1999;8371-8374.
37. Kubbutat M.H., Jones S.N., Vousden K.H. Regulation of p53 stability by MDM2. Nature. 387:1997;299-303.
38. Erhardt P., Tomaselli K.J., Cooper G.M. Identification of the MDM2 oncoprotein as a substrate for CPP32-like apoptotic proteases. J. Biol. Chem. 272:1997;15049-15052.
39. Chen L., Marechal V., Moreau J., Levine A.J., Chen J. Proteolytic cleavage of the MDM2 oncoprotein during apoptosis. J. Biol. Chem. 272:1997;22966-22973.
40. Pochampally R., Fodera B., Chen L., Shao W., Levine E.A., Chen J. A 60 kd MDM2 isoform is produced by caspase cleavage in non-apoptotic tumor cells. Oncogene. 17:1998;2629-2636.
41. Pochampally R., Fodera B., Chen L., Lu W., Chen J. Activation of an MDM2-specific caspase by p53 in the absence of apoptosis. J. Biol. Chem. 274:1999;15271-15277.
42. Tanimura S., Ohtsuka S., Mitsui K., Shirouzu K., Yoshimura A., Ohtsubo M. MDM2 interacts with MDMX through their RING finger domains. FEBS Lett. 447:1999;5-9.
43. Shvarts A., Steegenga W.T., Riteco N., van Laar T., Dekker P., Bazuine M., van Ham R.C., van der Houven van Oordt W., Hateboer G., van der Eb A.J., Jochemsen A.G. MDMX: a novel p53-binding protein with some functional properties of MDM2. EMBO J. 15:1996;5349-5357.
44. Canman C.E., Lim D.S., Cimprich K.A., Taya Y., Tamai K., Sakaguchi K., Appella E., Kastan M.B., Siliciano J.D. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science. 281:1998;1677-1679.
45. Tibbetts R.S., Brumbaugh K.M., Williams J.M., Sarkaria J.N., Cliby W.A., Shieh S.Y., Taya Y., Prives C., Abraham R.T. A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev. 13:1999;152-157.
46. Huang L.C., Clarkin K.C., Wahl G.M. p53-dependent cell cycle arrests are preserved in DNA-activated protein kinase-deficient mouse fibroblasts. Cancer Res. 56:1996;2940-2944.
47. Rathmell W.K., Kaufmann W.K., Hurt J.C., Byrd L.L., Chu G. DNA-dependent protein kinase is not required for accumulation of p53 or cell cycle arrest after DNA damage. Cancer Res. 57:1997;68-74.
48. Kachnic L.A., Wu B., Wunsch H., Mekeel K.L., DeFrank J.S., Tang W., Powell S.N. The ability of p53 to activate downstream genes p21(WAF1/cip1) and MDM2, and cell cycle arrest following DNA damage is delayed and attenuated in scid cells deficient in the DNA-dependent protein kinase. J. Biol. Chem. 274:1999;13111-13117.
49. Woo R.A., McLure K.G., Lees-Miller S.P., Rancourt D.E., Lee P.W. DNA-dependent protein kinase acts upstream of p53 in response to DNA damage. Nature. 394:1998;700-704.
50. Araki R., Fukumura R., Fujimori A., Taya Y., Shiloh Y., Kurimasa A., Burma S., Li G.C., Chen D.J., Sato K., Hoki Y., Tatsumi K., Abe M. Enhanced phosphorylation of p53 serine 18 following DNA damage in DNA-dependent protein kinase catalytic subunit-deficient cells. Cancer Res. 59:1999;3543-3546.
51. Hu M.C., Qiu W.R., Wang Y.P. JNK1, JNK2 and JNK3 are p53 N-terminal serine 34 kinases. Oncogene. 15:1997;2277-2287.
52. Chernov M.V., Ramana C.V., Adler V.V., Stark G.R. Stabilization and activation of p53 are regulated independently by different phosphorylation events. Proc. Natl. Acad. Sci. U.S.A. 95:1998;2284-2289.
53. Sakaguchi K., Herrera J.E., Saito S., Miki T., Bustin M., Vassilev A., Anderson C.W., Appella E. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev. 12:1998;2831-2841.
54. Lambert P.F., Kashanchi F., Radonovich M.F., Shiekhattar R., Brady J.N. Phosphorylation of p53 serine 15 increases interaction with CBP. J. Biol. Chem. 273:1998;33048-33053.
55. Thomas A., White E. Suppression of the p300-dependent MDM2 negative-feedback loop induces the p53 apoptotic function. Genes Dev. 12:1998;1975-1985.
56. Kapoor M., Lozano G. Functional activation of p53 via phosphorylation following DNA damage by UV but not gamma radiation. Proc. Natl. Acad. Sci. U.S.A. 95:1998;2834-2837.
57. Blaydes J.P., Hupp T.R. DNA damage triggers DRB-resistant phosphorylation of human p53 at the CK2 site. Oncogene. 17:1998;1045-1052.
58. Lu H., Fisher R.P., Bailey P., Levine A.J. The CDK7-cycH-p36 complex of transcription factor IIH phosphorylates p53, enhancing its sequence-specific DNA binding activity in vitro. Mol. Cell. Biol. 17:1997;5923-5934.
59. Sturzbecher H.W., Donzelmann B., Henning W., Knippschild U., Buchhop S. p53 is linked directly to homologous recombination processes via Rad51/Reca protein interaction. EMBO J. 15:1996;1992-2002.
60. Buchhop S., Gibson M.K., Wang X.W., Wagner P., Sturzbecher H.W., Harris C.C. Interaction of p53 with the human Rad51 protein. Nucleic Acids Res. 25:1997;3868-3874.
61. Marmorstein L.Y., Ouchi T., Aaronson S.A. The BRCA2 gene product functionally interacts with p53 and RAD51. Proc. Natl. Acad. Sci. U.S.A. 95:1998;13869-13874.
62. Zhang H., Somasundaram K., Peng Y., Tian H., Zhang H., Bi D., Weber B.L., El-Deiry W.S. BRCA1 physically associates with p53 and stimulates its transcriptional activity. Oncogene. 16:1998;1713-1721.
63. Jayaraman L., Murthy K.G., Zhu C., Curran T., Xanthoudakis S., Prives C. Identification of redox/repair protein Ref-1 as a potent activator of p53. Genes Dev. 11:1997;558-570.
64. Bunz F., Dutriaux A., Lengauer C., Waldman T., Zhou S., Brown J.P., Sedivy J.M., Kinzler K.W., Vogelstein B. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science. 282:1998;1497-1501.
65. Hermeking H., Lengauer C., Polyak K., He T.C., Zhang L., Thiagalingam S., Kinzler K.W., Vogelstein B. 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol. Cell. 1:1997;3-11.
66. Innocente S.A., Abrahamson J.L., Cogswell J.P., Lee J.M. p53 regulates a G2 checkpoint through cyclin B1. Proc. Natl. Acad. Sci. U.S.A. 96:1999;2147-2152.
67. Attardi L.D., Lowe S.W., Brugarolas J., Jacks T. Transcriptional activation by p53, but not induction of the p21 gene, is essential for oncogene-mediated apoptosis. EMBO J. 15:1996;3693-3701.
68. Canman C.E., Kastan M.B. Small contribution of G1 checkpoint control manipulation to modulation of p53-mediated apoptosis. Oncogene. 16:1998;957-966.
69. Soengas M.S., Alarcon R.M., Yoshida H., Giaccia A.J., Hakem R., Mak T.W., Lowe S.W. Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. Science. 284:1999;156-159.
70. Pan H., Yin C., Dyson N.J., Harlow E., Yamasaki L., Van Dyke T. Key roles for E2F1 in signaling p53-dependent apoptosis and in cell division within developing tumors. Mol. Cell. 2:1998;283-292.
71. Johnson T.M., Yu Z.X., Ferrans V.J., Lowenstein R.A., Finkel T. Reactive oxygen species are downstream mediators of p53-dependent apoptosis. Proc. Natl. Acad. Sci. U.S.A. 93:1996;11848-11852.
72. Venot C., Maratrat M., Dureuil C., Conseiller E., Bracco L., Debussche L. The requirement for the p53 proline-rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression. EMBO J. 17:1998;4668-4679.
73. Tan M., Li S., Swaroop M., Guan K., Oberley L.W., Sun Y. Transcriptional activation of the human glutathione peroxidase promoter by p53. J. Biol. Chem. 274:1999;12061-12066.
74. Yu J., Zhang Y., McIlroy J., Rordorf-Nikolic T., Orr G.A., Backer J.M. Regulation of the p85/p110 phosphatidylinositol 3′-kinase: stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit. Mol. Cell. Biol. 18:1998;1379-1387.
75. Yu J., Wjasow C., Backer J.M. Regulation of the p85/p110alpha phosphatidylinositol 3′-kinase. Distinct roles for the n-terminal and c-terminal SH2 domains. J. Biol. Chem. 273:1998;30199-30203.
76. Yin Y., Terauchi Y., Solomon G.G., Aizawa S., Rangarajan P.N., Yazaki Y., Kadowaki T., Barrett J.C. Involvement of p85 in p53-dependent apoptotic response to oxidative stress. Nature. 391:1998;707-710.
77. Zhu J., Jiang J., Zhou W., Zhu K., Chen X. Differential regulation of cellular target genes by p53 devoid of the PXXP motifs with impaired apoptotic activity. Oncogene. 18:1999;2149-2155.
78. Simms L.A., Radford-Smith G., Biden K.G., Buttenshaw R., Cummings M., Jass J.R., Young J., Meltzer S.J., Leggett B.A. Reciprocal relationship between the tumor suppressors p53 and BAX in primary colorectal cancers. Oncogene. 17:1998;2003-2008.
79. Shayesteh L., Lu Y., Kuo W.L., Baldocchi R., Godfrey T., Collins C., Pinkel D., Powell B., Mills G.B., Gray J.W. PIK3CA is implicated as an oncogene in ovarian cancer [see comments]. Nat. Genet. 21:1999;99-102.